Plus Therapeutics Presents Positive Interim ReSPECT-LM Phase 1 Data for Leptomeningeal Metastases at 2024 SNO/ASCO CNS Metastases Conference (GlobeNewswire) - Aug 12, 2024 - P1 | N=18 | ReSPECT-LM (NCT05034497) | Sponsor: Plus Therapeutics | "There were no dose limiting toxicities through cohort 4 and the maximum tolerated dose or maximum feasible dose was not reached. We observed a linear increase in absorbed radiation dose to the spinal fluid and ventricles and cranial subarachnoid space over 4 cohorts....The majority of adverse events (AEs) across all 4 cohorts were mild or moderate and unrelated or unlikely related to the study drug....Median overall survival for Cohorts 1-4 was 12 months with 8 of 16 patients alive at the time of analysis."
P1 data • Brain Cancer • CNS Tumor • Oncology • Solid Tumor
|